Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Muhimbili National Hospital, Dar es Salaam, Tanzania.
BMC Nephrol. 2024 Nov 21;25(1):419. doi: 10.1186/s12882-024-03840-3.
Renal dysfunction (RD) is more prevalent among people living with HIV (PLHIV) in sub-Saharan Africa (SSA) due to factors such as co-infections, hypertension, diabetes, and nephrotoxic antiretroviral drugs like tenofovir. Early detection of RD is critical but limited by resource constraints in many SSA countries, including Tanzania. Point-of-care (POC) tests, such as the Stat-Sensor Creatinine test by Nova Biomedical, present a cost-effective and non-invasive option for early detection. This study will evaluate the diagnostic performance of the Stat-Sensor creatinine test in detecting renal dysfunction in HIV care and treatment clinics (CTCs) in Tanzania. It will be conducted for a period of six months, from November 2024 to April 2025.
The study will measure point-of-care creatinine using a rapid creatinine dipstick against the standard serum creatinine test. The diagnostic performance and agreement to diagnose renal dysfunction will be assessed using a standardized statistical approach: Bland-Altman analysis and linear mixed-effects models to test agreement between creatinine dipstick tests with serum creatinine. Receiver operating characteristics (ROC) statistics will be used to test the diagnostic performance of the creatinine dipstick test to diagnose renal dysfunction.
We hypothesize that POC creatinine testing will show strong diagnostic performance, providing a reliable, rapid, and cost-efficient alternative for RD detection, leading to better patient outcomes and integration of POC tests into routine HIV care.
The study protocol was reviewed and approved by the Muhimbili University of Health and Allied Sciences Research and Publication committee in June 2024 with reference number, MUHAS-REC-05-2024-2275.
在撒哈拉以南非洲(SSA),由于合并感染、高血压、糖尿病和肾毒性抗逆转录病毒药物(如替诺福韦)等因素,感染艾滋病毒(HIV)的人群(PLHIV)中肾功能障碍(RD)更为普遍。早期发现 RD 至关重要,但在包括坦桑尼亚在内的许多 SSA 国家,由于资源有限,这一目标受到限制。即时检测(POC)测试,如 Nova Biomedical 的 Stat-Sensor 肌酐测试,为早期检测提供了一种具有成本效益且非侵入性的选择。本研究将评估 Stat-Sensor 肌酐测试在坦桑尼亚的 HIV 护理和治疗诊所(CTCs)中检测肾功能障碍的诊断性能。研究将在 2024 年 11 月至 2025 年 4 月期间进行,为期六个月。
本研究将使用快速肌酐试纸和标准血清肌酐测试测量即时点肌酐。使用标准化统计方法评估诊断性能和诊断肾功能障碍的一致性: Bland-Altman 分析和线性混合效应模型用于测试血清肌酐肌酐试纸测试之间的一致性。将使用接收者操作特征(ROC)统计来测试肌酐试纸测试诊断肾功能障碍的诊断性能。
我们假设 POC 肌酐检测将显示出良好的诊断性能,为 RD 检测提供可靠、快速且具有成本效益的替代方案,从而改善患者的预后,并将 POC 检测纳入常规 HIV 护理。
该研究方案于 2024 年 6 月由 Muhimbili 大学卫生与联合科学研究与出版委员会审查和批准,参考编号为 MUHAS-REC-05-2024-2275。